European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy

On 21 November 2016, the European Commission issued a marketing authorisation valid throughout the European Union for ixazomib in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Ixazomib was evalu...

Descripción completa

Detalles Bibliográficos
Autores principales: Tzogani, Kyriaki, Florez, Beatriz, Markey, Greg, Caleno, Mariapaola, Olimpieri, Odoardo Maria, Melchiorri, Daniela, Hovgaard, Doris Johanna, Sarac, Sinan Bardakci, Penttilä, Karri, Lapveteläinen, Tuomo, Salmonson, Tomas, Bergh, Jonas, Gisselbrecht, Christian, Pignatti, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735670/
https://www.ncbi.nlm.nih.gov/pubmed/31555488
http://dx.doi.org/10.1136/esmoopen-2019-000570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735670/
https://www.ncbi.nlm.nih.gov/pubmed/31555488
http://dx.doi.org/10.1136/esmoopen-2019-000570

Ejemplares similares